|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,756 GBX | -1.07% |
|
-2.98% | +21.09% |
| 04:26pm | GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies | MT |
| 02:03pm | GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- 2nd Update | DJ |
May 1 (Reuters) - GSK raised its full-year profit forecast on Wednesday, betting on strong demand for its common respiratory virus and shingles vaccines.
The London-listed drugmaker said it now expects a rise of 8% to 10% in annual adjusted earnings per share, up from the 6%-9% growth previously forecast.
It expects its sales to rise in the upper end of its 5% to 7% forecast range.
(Reporting by Eva Mathews in Bengaluru; Editing by Subhranshu Sahu)
| 1st Jan change | Capi. | |
|---|---|---|
| +21.09% | 91.96B | |
| +38.08% | 705B | |
| +32.82% | 583B | |
| -3.51% | 364B | |
| +20.50% | 332B | |
| +5.45% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +8.54% | 169B |
GSK PLC 
